Anzeige
Mehr »
Dienstag, 30.06.2026 - Börsentäglich über 12.000 News
China kontrolliert Seltene Erden - Brasilien könnte die Antwort sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
354 Leser
Artikel bewerten:
(2)

Syngene International: Syngene strengthens leadership team with two key appointments

Maninder Kapoor Puri joins as CHRO and Abhijit Zutshi as CCO

BENGALURU, India, May 4, 2026 /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the appointment of Maninder Kapoor Puri as Chief Human Resources Officer (CHRO) and Abhijit Zutshi as Chief Commercial Officer (CCO), effective 1 May 2026.

Maninder Kapoor Puri is a global HR leader with nearly three decades of experience driving business performance through people, leadership, culture, and digital HR ecosystems.

Her experience spans biopharmaceuticals, IT services, and consulting across North America, EMEA, and APAC. She has partnered with CEOs and Boards to lead large-scale, multi-market transformations, building high-performance organizations aligned to business growth.

Most recently, as CHRO at Biocon, she led enterprise-wide culture and leadership transformation. Prior to that, as Global CHRO at Mastek, she led HR across 40+ countries and has held leadership roles at Accenture and Firstsource Solutions. Maninder has been featured by Outlook Business as a face of "Viksit Bharat" and recognized among HR Today's Top 100 Global CHROs, India's Most Agile Leaders (2026), and as a CHRO of the Year.

As Chief Human Resources Officer and a member of the Executive Committee at Syngene, Maninder will be leading the company's global people agenda to support its next phase of growth.

Abhijit (Abhi) Zutshi joins Syngene as Chief Commercial Officer and will be based in the United States. As a member of the Executive Committee, Abhi will lead Syngene's commercial activities, including sales, client partnerships, marketing, brand building, digital initiatives, and account management.

Abhi is a seasoned pharmaceutical executive with nearly 27 years of commercial experience across global markets. He spent 25 years at Biocon, most recently as Chief Commercial Officer of the generics business, where he led both the drug substance and drug product divisions and built a global team focused on generic formulations. His career expertise spans sales, marketing, business development, portfolio management, and market entry strategy across small and large molecules. Earlier in his career, he held a product specialist role at Pfizer, where he led the India launch of the Zosyn brand. Abhi holds a degree in pharmacy, an MBA, and is a graduate of the Leadership Development Program at Harvard Business School.

Commenting on the appointments, Peter Bains, Managing Director and CEO, Syngene International, said, "We are pleased to welcome Maninder and Abhijit to Syngene's leadership team. Their depth of experience and strong track record in their respective domains will be instrumental as we continue to evolve our service offerings and enhance our value proposition for clients worldwide. These appointments reinforce our commitment to building a world-class leadership team capable of driving our next phase of sustainable growth."

About Syngene: Syngene International Ltd. (BSE: 539268) (NSE: SYNGENE) (ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's team of over 8,300 employees including 5,700+ scientists, brings both deep expertise and the capacity to deliver scientific excellence, robust data security, and world class manufacturing, at speed, to improve time-to market and lower the cost of innovation. With over 3 Mn sq. ft of specialized discovery, development, and manufacturing facilities across India and the U.S., Syngene works with ~400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis, and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company's latest Environmental, Social, and Governance (ESG) report, visit Syngene ESG Report.

Contact details:

Vijay Jeevanandham
Syngene International Limited
M: +91 8310914552
E: Vijay.Jeevanandham@syngeneintl.com

Alex Heeley / Abdul Khalifeh
De Facto Communications
T: +44 (0) 203 735 8165 / +44 (0) 7834784764
E: a.khalifeh@defacto.co.uk
E: a.heeley@defacto.co.uk

Cision View original content:https://www.prnewswire.co.uk/news-releases/syngene-strengthens-leadership-team-with-two-key-appointments-302761223.html

© 2026 PR Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.